NCARDIA
Ncardia, a leading provider of human iPSC-derived cell-based assays and services for drug discovery and development, announced today the launch of their DiscoverHIT drug screening platform. The new service enables researchers to access human disease-relevant biology earlier in the drug discovery process with the goal of bringing better medicines to patients faster.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190204005354/en/
The DiscoverHIT Platform is a phenotypic drug screening platform composed of four integrated modules:
- Disease models: Genetic and induced human iPSC-derived cardiac and neural disease models
- Large-scale manufacturing: Controlled bioreactor-based manufacturing to enable batch sizes compatible with high-throughput screening (HTS)
- Customized assay development: Generation and validation of disease-relevant assays with clinically relevant readouts
- High-throughput screening: Robust HTS using qualified disease assays in combination with high-content data acquisition and analysis
“Ncardia enables discovery with efficacy in mind from the start. To realize this, drug developers need validated human iPSC products at scale, disease models, the right assay systems and high-throughput screening. We’ve brought these components together in the DiscoverHIT platform.” stated Stefan Braam, CEO of Ncardia.
In addition to the four core modules of DiscoverHIT, Ncardia also offers access to a comprehensive compound library, scientific consultation, and the company’s newly founded training center, Ncardia Academy.
For more information on DiscoverHIT, visit ncardia.com/discoverhit .
About Ncardia
Ncardia (www.ncardia.com ) believes that stem cell technology will help give patients faster access to better and safer medicines by improving the drug discovery and development process. The company has 15 years of experience in developing and commercializing highly predictive human cellular assay systems for safety and efficacy screening of drug candidates. Ncardia operates globally and is based in Belgium, the Netherlands, Germany and the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005354/en/
Contact:
Steven Dublin steven.dublin@ncardia.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin25.6.2025 07:00:00 CEST | Press release
Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world4-6 IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO1,3,4 Enrollment for Galderma’s phase II studies of nemolizumab is planned to begin in H2 2025 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and C
MSCI Announces Results of the MSCI 2025 Market Classification Review24.6.2025 23:55:00 CEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today the results of the MSCI 2025 Market Classification Review. Select highlights of this year’s review includes MSCI: Extending the consultation on a potential reclassification of Bulgaria from Standalone to Frontier Market status Continuing to monitor the implementation and market adoption of measures to enhance the accessibility of the Korean equity market, to determine whether these measures have replicated the outcomes of fully operational offshore FX markets such as those found in Developed Markets Providing updates on the market classification status of Greece Continuing to monitor the market accessibility of the Bangladesh equity market “MSCI is committed to ensuring that our market classifications reflect the evolving realities of global accessibility and investability,” said Raman Aylur Subramanian, Head of Index R&D. “In 2025, we have see
Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors24.6.2025 22:15:00 CEST | Press release
NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company’s 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group (“LEGO”) from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. “Jørgen’s strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent addition to our board,” said Mark Parker, Executive Chairman of NIKE, Inc. “We look forward to working with Jørgen during an exciting time for NIKE where we will unlock our next chapter of growth through innovative product and distinctive brand storytelling across an integrated marketplace.” Prior to joining L
NetApp Appoints Disruptive Innovator Syam Nair as Chief Product Officer, Underscoring its Commitment to Bold Product Vision24.6.2025 22:05:00 CEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Syam Nair as its new Chief Product Officer (CPO), effective Monday, July 7, 2025. Nair succeeds Harv Bhela, who concluded his tenure in June following a successful chapter of product leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624871234/en/ Syam Nair, Chief Product Officer at NetApp Nair is a former Salesforce and Microsoft executive renowned as a maverick innovator in the industry, bringing over 25 years of experience in scaling cloud platforms and driving hyper-growth. In his new role, Nair will lead NetApp’s product and engineering teams to accelerate innovation in hybrid cloud and AI offerings and advance NetApp’s strategic vision for data-driven business growth. “I am thrilled to welcome Syam to NetApp’s leadership team. He joins us at a time when our customers are looking to NetApp to help them deli
Mirion Technologies and Westinghouse Partner to Drive Digital Innovation in Nuclear Instrumentation Systems24.6.2025 22:04:00 CEST | Press release
Based on Mirion’s proTK™ Product Line, the Newly Designed Solution Aims to Reduce Burden and Enhance Performance in Nuclear Power Plants. Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, and Westinghouse Electric Company LLC, a leading supplier of nuclear plant instrumentation and control systems, have announced a strategic partnership to provide digital Ex-core Nuclear Instrumentation Systems (NIS) based on the high-performing Mirion proTK product line. This collaboration aims to alleviate operator and maintenance burdens, enhance performance, and ensure sustained operation success. This digital NIS upgrade solution is offered exclusively through Westinghouse for both Westinghouse and Combustion Engineering designed PWRs worldwide. This initiative leverages Mirion’s proTK product line to upgrade existing analog neutron flux monitoring drawers, which were originally designed in the 1960s, to a state-of-the-art digital system. The Mirion proTK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom